[Form 4] Editas Medicine, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Editas Medicine director and CEO Gilmore O'Neill sold 5,592 shares of Editas Medicine (EDIT) on 09/03/2025 at $2.5961 per share under a pre-existing Rule 10b5-1 automatic sales plan. The filing states the sale was to satisfy tax withholding obligations arising from restricted stock units that vested on 09/02/2025 and was not a discretionary trade. After the transaction the reporting person beneficially owned 274,690 shares.

Positive

• Transaction executed under a pre-established Rule 10b5-1 plan, indicating it was non-discretionary
• Sale purpose disclosed: tax withholding for RSU vesting on 09/02/2025, providing transparency
• Post-transaction beneficial ownership disclosed: 274,690 shares, allowing assessment of insider alignment

Negative

• Reporting person sold 5,592 shares, which reduces insider shareholdings
• Price per share was $2.5961, indicating the sale occurred at a low absolute price level (context of broader valuation not provided)

Insights

Corporate Governance Expert

TL;DR: Sale executed under a pre-established 10b5-1 plan to cover tax withholding for vested RSUs; non-discretionary.

The filing clearly indicates the transaction was executed under a durable automatic sales instruction plan adopted April 13, 2022, which supports the reporting person’s claim that the trade was non-discretionary. The sale quantity of 5,592 shares at $2.5961 was explicitly to satisfy tax withholding from RSU vesting on 09/02/2025. This is a routine insider liquidity event tied to compensation vesting rather than a market-timed disposition, reducing ambiguity about intent. The remaining beneficial ownership of 274,690 shares is disclosed, allowing investors to assess continued insider alignment.

Securities Analyst

TL;DR: Insider sold a modest number of shares; transaction appears administrative not indicative of company fundamentals.

The sale of 5,592 shares is explicitly linked to tax withholding for vested restricted stock units and was executed pursuant to a Rule 10b5-1 plan. The report provides clear transaction date, price, and post-sale beneficial ownership. There is no disclosure here of additional sales or changes to executive roles. From a market-impact perspective the transaction size relative to total outstanding shares is not provided, so materiality to valuation cannot be assessed from this filing alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Neill Gilmore Neil

(Last) (First) (Middle)

C/O EDITAS MEDICINE, INC.

11 HURLEY ST.

(Street)

CAMBRIDGE MA 02141

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Editas Medicine, Inc. [ EDIT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		S(1)		5,592	D	$2.5961	274,690	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2025. The sale does not represent a discretionary trade by the Reporting Person.

Remarks:

	/s/ Gilmore O'Neill	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Editas Medicine insider Gilmore O'Neill do on 09/03/2025?

The filing shows Gilmore O'Neill sold 5,592 shares of Editas Medicine on 09/03/2025 at $2.5961 per share.

Why were the shares sold by the reporting person?

The sale was to satisfy tax withholding obligations arising from restricted stock units that vested on 09/02/2025 and was executed under a 10b5-1 plan.

Was the sale discretionary or part of a plan?

The sale was executed pursuant to a durable automatic sales instruction (Rule 10b5-1) plan adopted April 13, 2022, and the filing states it was not a discretionary trade.

How many shares does Gilmore O'Neill own after this transaction?

After the reported sale the filing discloses 274,690 shares beneficially owned by the reporting person.

Does the filing indicate any other transactions or role changes?

No. The Form 4 only discloses this sale related to RSU tax withholding and lists the reporting person as Director and CEO.